Skip to content

Author

M. Carlo

We have 3 of 225 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

24 A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)

Abstract Background There is a need for novel systemic therapies in patients with metastatic renal cell carcinoma (RCC) who progress on standard agents. A hallmark of clear cell RCC (ccRCC) is von Hippel Lindau (VHL) inactivation which affects downstream targets including vascular endothelial growth factor (VEGF). It a...

Sahil D. Doshi, Y. Ged, Andrea Knezevic et al. · 0 citations
Sep 2026

Impact of Age on Outcomes in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT).

BACKGROUND Malignancies arising in young adults often exhibit biological and clinical behaviors distinct from those in older patients. Limited data exist on the prognostic impact of age in metastatic non-clear cell renal cell carcinoma (mnccRCC). This study compared survival outcomes by age using the large-scale TriNet...

A. Cigliola, Nazli Dizman, C. Mercinelli et al. · 0 citations
Open access Aug 2026

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Using large, unselected pan-cancer cohorts and integrated tumor and genomic analysis can help refine the phenotype of rare cancer predisposition syndromes and suggest novel cancer associations, including BAP1 PVs in hepatobiliary cancers and FLCN in colorectal cancer.

M. Carlo, Andrew Schroeder, Jie Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.